PER-009-01已完成未知
Randomized, Double Blind, Parallel Group, Controlled with Placebo Study performed Under Internal Blind Conditions whose Purpose is to Examine the Safety, Tolerability and Efficacy of MK-0869 for the Prevention of Nausea and Vomiting Induced by Chemotherapy Associated with Administration of High doses of Cisplatin.
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2001年3月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The patient is an adult with an age of> 18 years.
- •The patient is expected to receive his or her first series of cisplatin chemotherapy for a histologically documented solid tumor at a dose of> 70 mg / m ^ administered in <3 hours.
- •Premenopausal patients must accredit a negative pregnancy test with sensitivity of 25 IU in serum or urine in the Pre-study visit and agree to use an appropriate contraceptive method at least 14 days before, from start to finish , and at least 14 days after the last dose of study medication. Women who take oral contraceptives should agree to add a form of barrier contraception.
- •The patient has a Kamofsky score of> 60.
- •The patient has a life expectancy of> 3 months.
- •The patient is able to read, understand and complete the questionnaires and the study diary, including the questions that require a response according to the visual analog scale (VAS).
- •The patient understands the procedures and agrees to participate in the study by providing written informed consent.
排除标准
- •The patient is mentally incapacitated or has an important emotional or psychiatric disorder that in the opinion of the investigator prevents their admission to the study.
- •The patient currently uses illicit drugs or there is current evidence of alcohol consumption (as defined by the criteria mentioned in the DSM-IV) determined by the investigator.
- •The patient will receive a stem cell rescue therapy along with the course of cisplatin chemotherapy.
- •The patient will receive an unauthorized (investigational) drug during the last 4 weeks.
- •Abnormal laboratory values: - Absolute neutrophil count <1 500 mm3 and Leukocyte count <3000 / mm3, Platelet count <100,000 / mm3, AST> 2.5 X upper limit of normal, ALT> 2.5 X upper limit of the normal, Bilirubin> 1.5 x upper limit of normal, Creatinine> 1.5 x upper limit of normal
- •The patient has a history of diseases that, in the opinion of the investigator, could confuse the results of the study or represent an unjustified risk when administering the study drug to the patient.
- •The patient has an active infection (for example, pneumonia) or any uncontrolled disease (for example, diabetic ketoacidosis, gastrointestinal obstruction) except for a tumor that in the opinion of the investigator could confuse the results of the study or represent an unjustified risk in administering the Study drug to the patient.
- •The patient will receive a multi-day chemotherapy with cisplatin in a single cycle.
- •The patient will receive a chemotherapy of moderate or high emetogenicity (Hesketh Level 3 or higher, Appendix 2) 6 days before and / or after the day on which cisplatin infusion is performed
- •The patient has been treated with the following antiemetic agents within 48 hours of Day 1 of the Study: 5-HT3 antagonists (ondansetron, granisetron, dolasetron, or tropisetron), phenothiazines (eg, prochlorperazine, flufenacin, perphenazine, triethylperazine, or chlorpromazine) ), butyrophenones (for example, haloperidol or droperidol), benzamides (for example, metoclopramide or alizapride), domperidone, cannabinoids
- •The patient has started benzodiazepine therapy within 48 hours of Day 1 of the Study, except for single daily doses of triazolam, termazepam or midazolam.
- •The patient has initiated systemic corticosteroid therapy within 72 hours of Day 1 of the Study, except as described in the protocol or as premedication for patients receiving paclitaxel or docetaxel (see Appendix 4). Patients who are receiving daily chronic steroid therapy (> 72 hours) may enroll as long as the dose of steroids is not> 10 mg of prednisone daily or equivalent.
- •The patient has vomited and / or has retched within 24 hours before the start of the cisplatin infusion on Day 1 of the Study in Cycle 1.
- •The patient has received or will receive radiation therapy to the abdomen (this includes from the level of the diaphragm or below) or pelvis within 1 week before or between Days 1 to 6 of the Study in Cycle 1.
- •The patient has a primary or metastatic CNS tumor.
- •The patient takes or has taken within 7 days of Day 1 of the Study: terfenadine, cisapride, astemizole, clarithromycin (the use of azithromycin, erythromycin and roxithromycin is recommended), ketoconazole or itraconazole (the use of fluconazole is allowed), amifostine
- •The patient takes or has taken within 30 days of Day 1 of the Study: barbiturates, rifampicin or rifabutin, phenytoin or carbamazepine
研究者
相似试验
尚未招募
不适用
A clinical based study to find out the exact lowest possible dose of ketamine, a drug which takes care of the pain and also helps in maintaining the state of anaesthesia during surgery, in keeping the patient pain free in the period after Laparoscopic Cholecystectomy surgery.CTRI/2020/01/022983Midnapore Medical College
进行中（未招募）
不适用
Randomized, single-blind, parallel groups, controlled study to compare levofloxacin and prulifloxacin in patients with exacerbations of COPD previously treated with different antibiotics and admitted to Internal Medicine Departments - NDEUCTR2008-003842-27-ITCENTRO STUDI FADOI
已完成
3 期
A clinical trial to test the effectiveness of 2 drugs, a combination product {Ebastine (anti-histaminic or cold medication) plus Montelukast (anti-allergic medication)} in comparison with Ebastine (anti-histaminic or cold medication) in the treatment of patients with allergic rhinitis.CTRI/2013/07/003797Micro Labs Limited541
进行中（未招募）
不适用
Effects of Depth of Neuromuscular Blockade and Insufflation Pressure on Surgical ConditionsPatients undergoing elective in-patient laparoscopic cholecystectomy procedures under general anesthesia with neuromuscular relaxation and active reversal of neuromuscular blockadeMedDRA version: 14.1Level: LLTClassification code 10018061Term: General anesthesiaSystem Organ Class: 100000004865EUCTR2012-001886-33-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.120
进行中（未招募）
1 期
Effects of Depth of Neuromuscular Blockade and Insufflation Pressure on Surgical Conditions.Patients undergoing elective in-patient laparoscopic cholecystectomy procedures under general anesthesia with neuromuscular relaxation and active reversal of neuromuscular blockade.MedDRA version: 14.1 Level: LLT Classification code 10018061 Term: General anesthesia System Organ Class: 100000004865EUCTR2012-001886-33-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.127